Skip to main content

Advertisement

SpringerLink
Log in

Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Autoimmune blistering diseases are associated with autoantibodies to desmosomal (pemphigus group) or hemidesmosomal proteins (autoimmune subepidermal blistering disorders) that are essential for the structural integrity of the epidermis and dermoepidermal junction. Treatment is usually based on systemic glucocorticosteroids, which are often combined with additional immunosuppressants such as azathioprine and mycophenolate mofetil or immunomodulators including dapsone, antibiotics, and intravenous immunoglobulins. These interventions are sometimes not sufficient to induce remission and/or may be associated with intolerable adverse events. In such situations, the anti-CD20 antibody rituximab has been successfully applied in recent years. Rituximab transitorily depletes CD20-positive B lymphocytes from the circulation. It has been employed in more than 1 million patients with CD20-positive non-Hodgkin’s lymphoma and severe side effects were only rarely observed. Subsequently, the B cell-modulating effect of rituximab has encouraged its use in a variety of autoimmune diseases, including more than 40 patients with pemphigus. In addition, a few patients with bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita have received rituximab. In the majority of these patients, clinical remission was induced; however, serious adverse events were considerable higher compared to both patients with non-Hodgkin’s lymphoma or nonbullous autoimmune disorders like lupus erythematosus, dermatomyositis, and rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Schmidt E, Zillikens D (2000) Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 16:113–157

    PubMed  CAS  Google Scholar 

  2. Stanley JR, Amagai M (2006) Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 355:1800–1810

    Article  PubMed  CAS  Google Scholar 

  3. Harman KE, Albert S, Black MM (2003) Guidelines for the management of pemphigus vulgaris. Br J Dermatol 149:926–937

    Article  PubMed  CAS  Google Scholar 

  4. Goebeler M, Sitaru C, Zillikens D (2004) Bullous autoimmune disorders: therapy. J Dtsch Dermatol Ges 2:774–793

    Article  PubMed  Google Scholar 

  5. Goebeler M, Zillikens D (2006) Bullous pemphigoid: diagnosis and management. Expert Review of Dermatology 1:401–411

    Article  CAS  Google Scholar 

  6. Cohen Y, Solal-Celigny P, Polliack A (2003) Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 88:811–823

    PubMed  CAS  Google Scholar 

  7. George JN, el-Harake MA, Raskob GE (1994) Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331:1207–1211

    Article  PubMed  CAS  Google Scholar 

  8. Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77:24–28

    PubMed  CAS  Google Scholar 

  9. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    Article  PubMed  CAS  Google Scholar 

  10. Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564–576

    Article  PubMed  CAS  Google Scholar 

  11. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580–3590

    Article  PubMed  CAS  Google Scholar 

  12. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613–620

    Article  PubMed  CAS  Google Scholar 

  13. Vugmeyster Y, Howell K (2005) Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol 4:1117–1124

    Article  CAS  Google Scholar 

  14. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459

    Article  PubMed  CAS  Google Scholar 

  15. Janas E, Priest R, Wilde JI, White JH, Malhotra R (2005) Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139:439–446

    Article  PubMed  CAS  Google Scholar 

  16. Schmidt E, Obe K, Bröcker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174–178

    Article  PubMed  CAS  Google Scholar 

  17. Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D (2005) Induction of dermal–epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 115:870–878

    Article  PubMed  CAS  Google Scholar 

  18. Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888

    Article  PubMed  CAS  Google Scholar 

  19. Schmidt E, Hunzelmann N, Zillikens D, Broecker EB, Goebeler M (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503–508

    Article  PubMed  CAS  Google Scholar 

  20. Schmidt E, Seitz CS, Benoit S, Bröecker EB, Goebeler M (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352–356

    Article  PubMed  CAS  Google Scholar 

  21. Belgi AS, Azeez M, Hoyle C, Williams RE (2006) Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 31:143

    Article  PubMed  CAS  Google Scholar 

  22. Kong HH, Prose NS, Ware RE, Hall RP 3rd (2005) Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 22:461–464

    Article  PubMed  Google Scholar 

  23. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772–1779

    Article  PubMed  CAS  Google Scholar 

  24. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A (2001) Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137:269–272

    PubMed  CAS  Google Scholar 

  25. Barnadas M, Roe E, Brunet S, Garcia P, Bergua P, Pimentel L, Puig L, Francia A, Garcia R, Gelpi C, Sierra J, Coll P, Alomar A (2006) Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 20:69–74

    Article  PubMed  Google Scholar 

  26. Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S (2006) Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol 86:87–89

    PubMed  Google Scholar 

  27. Borel C, Launay F, Garrouste C, Astudillo L, Bazex J, Arlet P, Paul C, Viraben R, Sailler L (2006) Rituximab induced remission of pemphigus vulgaris: 2 cases. Rev Med Interne 28:266–268

    Article  PubMed  Google Scholar 

  28. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M (2006) Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 16:266–270

    PubMed  Google Scholar 

  29. McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT (2006) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol 55:143–148

    Article  PubMed  Google Scholar 

  30. Sadler E, Schafleitner B, Lanschuetzer C, Laimer M, Pohla-Gubo G, Hametner R, Hintner H, Bauer JW (2007) Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol 157:417–419

    Article  PubMed  CAS  Google Scholar 

  31. Goebeler M, Herzog S, Bröcker EB, Zillikens D (2003) Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 149:899–901

    Article  PubMed  CAS  Google Scholar 

  32. Arin MP, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620–625

    Article  PubMed  CAS  Google Scholar 

  33. Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J (2002) Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 30:327–329

    Article  PubMed  CAS  Google Scholar 

  34. Schmidt E, Benoit S, Bröcker EB, Zillikens D, Goebeler M (2006) Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 142:147–150

    Article  PubMed  Google Scholar 

  35. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612–3622

    Article  PubMed  CAS  Google Scholar 

  36. Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H (2004) Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140:91–96

    Article  PubMed  CAS  Google Scholar 

  37. Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M (2005) Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 153:449–451

    Article  PubMed  CAS  Google Scholar 

  38. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741–750

    Article  PubMed  CAS  Google Scholar 

  39. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580–2589

    Article  PubMed  CAS  Google Scholar 

  40. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601–607

    Article  PubMed  CAS  Google Scholar 

  41. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623–627

    Article  PubMed  CAS  Google Scholar 

  42. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511–1513

    Article  PubMed  CAS  Google Scholar 

  43. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861

    Article  PubMed  CAS  Google Scholar 

  44. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639–2642

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

    Enno Schmidt & Eva-Bettina Bröcker

  2. Department of Dermatology, University of Heidelberg, University Medical Center Mannheim, Theodor Kutzner-Ufer 1-3, 68135, Mannheim, Germany

    Matthias Goebeler

Authors
  1. Enno Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva-Bettina Bröcker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Goebeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Enno Schmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, E., Bröcker, EB. & Goebeler, M. Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders. Clinic Rev Allerg Immunol 34, 56–64 (2008). https://doi.org/10.1007/s12016-007-8021-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-8021-6

Keywords

Search

Navigation